The first 13-year-old patient

The first 13-year-old patient   By Merrill Goozner FEATURE ARTICLE Beating MalariaNicholas White and François Nosten have shown that drugs in combination with artemisinin are 90% effective at fighting the scourge of the world. So why isn't everyone using it? MERRILL GOOZNER travels to Thailand and China to watch Nosten and White at work. ARTICLE EXTRAS A military outbreak spurs researchIn September 2003, the US 26th Marine Expeditionary Unit entered Liberia for a

Written byMerrill Goozner
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

By Merrill Goozner

Nicholas White and François Nosten were not the first clinicians to use artemisinin in a human trial. That honor belongs to Li Guoqian, now a senior professor at the Guangzhou University of Traditional Chinese Medicine (GUTCM).

Military necessity has always been a major driver of antimalarial therapeutic advances, and when Vietnam president Ho Chi Minh asked Chinese Community Party leader Mao Zedong for help in combating a disease that was disabling more of his soldiers than were American bombs during the Vietnam War, traditional Chinese medicine, especially qinghaosu, seemed like a good place to start. (At the time, both Vietnam and China were cut off from global supplies of chloroquine, then the drug of choice for treating malaria.)

Mao, in the midst of unleashing a Cultural Revolution that would temporarily destroy schools that taught western medicine, asked Zhou En Lai to establish a military research project on ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies